Mineralys Therapeutics, INC Form 4 insider transactions

Brian Taylor Slingsby, a director and 10% owner of Mineralys Therapeutics, acquired 259,259 shares of common stock at $13.50 per share on March 13, 2025.

Chief Medical Officer David Malcom Rodman of Mineralys Therapeutics, Inc. exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Adam Levy, CFO and Secretary of Mineralys Therapeutics, sold 10,757 shares of common stock at a weighted-average price of $12.0558 per share on April 11, 2025, under a pre-arranged 10b5-1 trading plan.

Mineralys Therapeutics CEO Jon Congleton sold 15,319 shares of common stock at a weighted-average price of $12.1942 on April 11, 2025, under a pre-arranged Rule 10b5-1 trading plan.

David Malcom Rodman, Chief Medical Officer of Mineralys Therapeutics, sold shares of MLYS common stock on April 1, 2025, under a pre-arranged 10b5-1 trading plan.

Samsara BioCapital, a significant shareholder in Mineralys Therapeutics, has increased its holdings through a recent purchase of 600,000 shares of common stock.

Director Srinivas Akkaraju reports the acquisition of 600,000 shares of Mineralys Therapeutics at $13.50 per share through Samsara BioCapital, L.P.

RA Capital Management and related entities acquired 1,296,296 shares of Mineralys Therapeutics at $13.50 per share, increasing their indirect holdings.

David Malcom Rodman, Chief Medical Officer of Mineralys Therapeutics, exercised stock options on March 12, 2025.

RA Capital Management and related entities report the acquisition of stock options in Mineralys Therapeutics, Inc.

Adam Levy, CFO and Secretary of Mineralys Therapeutics, reports the acquisition of stock options.

David Malcom Rodman, Chief Medical Officer of Mineralys Therapeutics, reports acquisition of stock options.

Director Akkaraju Srinivas and Samsara BioCapital, L.P. report acquisition of stock options in Mineralys Therapeutics.

Brian Taylor Slingsby, a director and 10% owner of Mineralys Therapeutics, Inc., transferred 32,900 stock options to Catalys Pacific Fund, LP on February 13, 2025.

Director Derek DiRocco acquired stock options in Mineralys Therapeutics, Inc. on February 13, 2025.

Director Alexander M. Gold of Mineralys Therapeutics, Inc. reports acquisition of stock options.

Mineralys Therapeutics CEO, Jon Congleton, was granted stock options for 570,000 shares on February 13, 2025, vesting monthly over four years.

Daphne Karydas, a director of Mineralys Therapeutics, reported the acquisition of stock options.

Director Glenn Sblendorio of Mineralys Therapeutics, Inc. [MLYS] acquired stock options on February 13, 2025.

David Malcom Rodman, Chief Medical Officer of Mineralys Therapeutics, reports exercising stock options and related transactions involving common stock.

Mineralys Therapeutics CFO and Secretary, Adam Levy, sold 10,757 shares of common stock on January 13, 2025, under a pre-arranged 10b5-1 trading plan.

David Malcom Rodman, Chief Medical Officer of Mineralys Therapeutics, exercised stock options and acquired common stock on January 13, 2025.

Mineralys Therapeutics CEO, Jon Congleton, sold 18,333 shares of common stock at a weighted average price of $9.0592 per share, as part of a pre-arranged 10b5-1 trading plan.

Brian Taylor Slingsby, a director at Mineralys Therapeutics, transferred 22,000 stock options to Catalys Pacific Fund, LP.

David Malcom Rodman, Chief Medical Officer of Mineralys Therapeutics, exercised stock options for 5,017 shares at a price of $0.54 per share.

Mineralys Therapeutics' Chief Medical Officer, David Malcom Rodman, exercised stock options and sold shares under a pre-arranged trading plan.

David Malcom Rodman, Chief Medical Officer of Mineralys Therapeutics, exercised stock options and sold shares on November 6, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Adam Levy, CFO and Secretary of Mineralys Therapeutics, sold 10,757 shares of common stock at a weighted-average price of $13.5729 on October 11, 2024, under a pre-arranged 10b5-1 trading plan.

David Malcom Rodman, Chief Medical Officer of Mineralys Therapeutics, recently exercised stock options at prices of $0.54 and $1.08, acquiring a total of 10,369 shares.

Mineralys Therapeutics CEO Jon Congleton sold 15,271 shares of common stock at a weighted average price of $13.518 per share on October 11, 2024, under a pre-arranged Rule 10b5-1 trading plan.